End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
100.50 CHF | +4.75% |
|
+4.25% | +2.84% |
02-11 | DSM-Firmenich to Sell Feed Enzymes Alliance JV Share to Partner for $1.55 Billion | DJ |
02-11 | Novonesis to buy DSM-Firmenich's stake in enzymes venture for $1.6 bln | RE |
Summary: DSM-Firmenich
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: DSM-Firmenich
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses: DSM-Firmenich
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 59.21 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings Chart: DSM-Firmenich
ESG chart: DSM-Firmenich
Fundamentals | Valuation | Revisions of Fundamental Estimates | Capi.($) | ||
---|---|---|---|---|---|
27.43B | |||||
135B | |||||
121B | |||||
81.47B | |||||
76.39B | |||||
47.77B | |||||
32.72B | |||||
Average | 74.46B | ||||
Weighted average by Cap. |
Financials
Valuation
Revisions
Consensus
Business Predictability
ESG
Technical analysis
- Stock Market
- Equities
- DSFIR Stock
- Ratings DSM-Firmenich

MarketScreener is also available in this country: United States.
Switch edition